Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France19 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 2,000 people, planned
- Started
- 9 Jul 2026
- Expected to end
- 9 Jul 2031
- Type of study
- Interventional, 24 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tocilizumab
- Baricitinib
- Anakinra
- Hydrocortisone
- Hydrocortisone and fludrocortisone
- Heparin
- Low molecular weight heparin
- Recombinant humanThrombomodulin( rhTM)
- Sivelestat
- Usual care
- blood purification with MTx.100 Plasma Adsorption Column
- G-CSF filgrastim
- Interferon gamma-1b
- Fludrocortisone
- Prophylactic unfractionated heparin (UFH)
- Octaplas LG
- Plasminogen
- Record updated
- 20 October 2026
Who can take part
- Age
- 37 weeks and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Other criteria
- Platform inclusion criteria will be:
- All genders patients
- Aged >37 weeks corrected gestational age
- Sepsis as per Sepsis-3 definition for adults, and as per the PHOENIX sepsis for children; Briefly, all following criteria will be required:
- Documented or suspected infection,
- Sequential Organ Failure Assessment (SOFA) score ≥2 for adults, and PHOENIX sepsis score of ≥2 for children; Health insurance; Platform exclusion criteria:; Any of the following:
- Refusal to consent for participating in the study,
- Pregnancy measured by beta-HCG blood levels
- Breast feeding
- Acute coronary disease in the past 3 months
- Stroke episode in the past 3 months
- Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study; Treatable trait inclusion criteria :
- Hyperinflammation : Subphenotypes Beta, Delta, Gamma for adults; Subphenotypes PedSep-B, C, D for children
- Hypoinflammation : lymphocytes count < 1.0 × 10\^9/L
- Macrophage Activation Like Syndrome : Ferritin >4,420 ng/mL for adults, Ferritin >500 ng/mL for children
- Corticosteroids: Positive for i-RECORDS algorithm signature
- Hypercoagulation (adults) : Prothrombin time (PT)/INR ≥ 1.40 AND Platelet count < 150 000/mm3 or greater than 30% decrease in platelets in 24 hours
- Hypofibrinolysis (adults): Plasminogen deficit < 0.5 µmol/L; There are also inclusion and exclusion criteria related to treatable traits and interventions
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.
The 24 groups in the trial
- Hyperinflammation : TocilizumabTreatment being tested
Treatment: Tocilizumab
- Hyperinflammation: BaricitinibTreatment being tested
Treatment: Baricitinib
- Hyperinflammation: AnakinraTreatment being tested
Treatment: Anakinra
- Hyperinflammation : blood purification with MTx.100 Plasma Adsorption ColumnTreatment being tested
Treatment: blood purification with MTx.100 Plasma Adsorption Column
- Hyperinflammation : usual careExisting treatment, for comparison
Treatment: Usual care
- Hypoinflammation : G CSF filgrastimTreatment being tested
Treatment: Heparin and G-CSF filgrastim
- Hypoinflammation : Interferon gamma-1bTreatment being tested
Treatment: Interferon gamma-1b
- Hypoinflammation : usual careExisting treatment, for comparison
Treatment: Usual care
- MALS : AnakinraTreatment being tested
Treatment: Anakinra
- MALS : blood purification with MTx.100 Plasma Adsorption ColumnTreatment being tested
Treatment: blood purification with MTx.100 Plasma Adsorption Column
- MALS : usual careExisting treatment, for comparison
Treatment: Usual care
- Corticoids response : HydrocortisoneTreatment being tested
Treatment: Hydrocortisone
- Corticoids response : FludrocortisoneTreatment being tested
Treatment: Fludrocortisone
- Corticoids response : Hydrocortisone + FludrocortisoneTreatment being tested
Treatment: Hydrocortisone and fludrocortisone
- Corticoids response : usual careExisting treatment, for comparison
Treatment: Usual care
- Hypercoagulation : Prophylactic unfractionated heparin (UFH)Treatment being tested
Treatment: Prophylactic unfractionated heparin (UFH)
- Hypercoagulation : Therapeutic UFHTreatment being tested
Treatment: Heparin
- Hypercoagulation : Therapeutic low molecular weight heparin (LMWH)Treatment being tested
Treatment: Low molecular weight heparin
- Hypercoagulation : ThrombomodulinTreatment being tested
Treatment: Recombinant humanThrombomodulin( rhTM)
- Hypercoagulation : usual careExisting treatment, for comparison
Treatment: Usual care
- Hypofrinolysis : SivelestatTreatment being tested
Treatment: Sivelestat
- Hypofrinolysis : OctaplasLGTreatment being tested
Treatment: Octaplas LG
- Hypofrinolysis : PlasminogenTreatment being tested
Treatment: Plasminogen
- Hypofrinolysis : Usual careExisting treatment, for comparison
Treatment: Usual care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
- Record updated
- 20 October 2026